These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 21332732)

  • 41. Clinical applications of adoptive natural killer cell immunotherapy for cancer: current status and future prospects.
    Guo H; Qian X
    Onkologie; 2010; 33(7):389-95. PubMed ID: 20631487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Natural-killer-cell-based treatment in haematopoietic stem-cell transplantation.
    Passweg JR; Koehl U; Uharek L; Meyer-Monard S; Tichelli A
    Best Pract Res Clin Haematol; 2006; 19(4):811-24. PubMed ID: 16997185
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation.
    Pati AR; Godder K; Lamb L; Gee A; Henslee-Downey PJ
    Bone Marrow Transplant; 1995 Jun; 15(6):979-81. PubMed ID: 7581101
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Alternative donors hematopoietic stem cells transplantation for adults with acute myeloid leukemia: Umbilical cord blood or haploidentical donors?
    Ruggeri A; Ciceri F; Gluckman E; Labopin M; Rocha V;
    Best Pract Res Clin Haematol; 2010 Jun; 23(2):207-16. PubMed ID: 20837332
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Natural-killer cell amplification for adoptive leukemia relapse immunotherapy: comparison of three cytokines, IL-2, IL-15, or IL-7 and impact on NKG2D, KIR2DL1, and KIR2DL2 expression.
    Decot V; Voillard L; Latger-Cannard V; Aissi-Rothé L; Perrier P; Stoltz JF; Bensoussan D
    Exp Hematol; 2010 May; 38(5):351-62. PubMed ID: 20172016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Facilitating T-cell immune reconstitution after haploidentical transplantation in adults.
    Waller EK; Giver CR; Rosenthal H; Somani J; Langston AA; Lonial S; Roback JD; Li JM; Hossain MS; Redei I
    Blood Cells Mol Dis; 2004; 33(3):233-7. PubMed ID: 15528137
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self.
    Ruggeri L; Aversa F; Martelli MF; Velardi A
    Immunol Rev; 2006 Dec; 214():202-18. PubMed ID: 17100886
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A pilot study of cytoreductive chemotherapy combined with infusion of additional peripheral blood stem cells reserved at time of harvest for transplantation in case of relapsed hematologic malignancies after allogeneic peripheral blood stem cell transplant.
    Kim JG; Sohn SK; Kim DH; Lee NY; Suh JS; Lee KS; Lee KB
    Bone Marrow Transplant; 2004 Jan; 33(2):231-6. PubMed ID: 14647258
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Donor lymphocyte infusion for leukemia relapse after hematopoietic stem cell transplantation.
    Yegin ZA; Ozkurt ZN; Aki SZ; Sucak GT
    Transfus Apher Sci; 2010 Jun; 42(3):239-45. PubMed ID: 20385512
    [TBL] [Abstract][Full Text] [Related]  

  • 51. IL-2-driven regulation of NK cell receptors with regard to the distribution of CD16+ and CD16- subpopulations and in vivo influence after haploidentical NK cell infusion.
    Huenecke S; Zimmermann SY; Kloess S; Esser R; Brinkmann A; Tramsen L; Koenig M; Erben S; Seidl C; Tonn T; Eggert A; Schramm A; Bader P; Klingebiel T; Lehrnbecher T; Passweg JR; Soerensen J; Schwabe D; Koehl U
    J Immunother; 2010; 33(2):200-10. PubMed ID: 20145545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Allogeneic peripheral blood progenitor cells for treatment of relapse after bone marrow transplantation.
    Glass B; Majolino I; Dreger P; Scimè R; Santoro A; Vasta S; Suttorp M; Haferlach T; Schmitz N
    Bone Marrow Transplant; 1997 Oct; 20(7):533-41. PubMed ID: 9337054
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Experimental study on IL-2- and IL-15 application in allogeneic hematopoietic stem cell transplantation].
    Chen GH; Wu DP; Sun AN; Yang MZ; Wang Y; Tang XW; Chang HR; Feng YF; Zhu ZL
    Zhonghua Xue Ye Xue Za Zhi; 2008 Aug; 29(8):526-30. PubMed ID: 19112915
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Haploidentical allogeneic hematopoietic cell transplantation in adults using CD3/CD19 depletion and reduced intensity conditioning: an update.
    Bethge WA; Faul C; Bornhäuser M; Stuhler G; Beelen DW; Lang P; Stelljes M; Vogel W; Hägele M; Handgretinger R; Kanz L
    Blood Cells Mol Dis; 2008; 40(1):13-9. PubMed ID: 17869547
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sequential recovery of NK cell receptor repertoire after allogeneic hematopoietic SCT.
    Giebel S; Dziaczkowska J; Czerw T; Wojnar J; Krawczyk-Kulis M; Nowak I; Holowiecka A; Segatti A; Kyrcz-Krzemien S; Kusnierczyk P; Holowiecki J
    Bone Marrow Transplant; 2010 Jun; 45(6):1022-30. PubMed ID: 20118994
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Alloreactive donor lymphocytes (DLI) after allogeneic hematopoietic stem cell transplantation (HSCT): study of toxicity and efficacy].
    Michallet AS; Nicolini F; Michallet M
    Bull Cancer; 2003; 90(8-9):758-62. PubMed ID: 14609766
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Conflicting impact of alloreactive NK cells on transplantation outcomes after haploidentical transplantation: do the reconstitution kinetics of natural killer cells create these differences?
    Zhao XY; Chang YJ; Huang XJ
    Biol Blood Marrow Transplant; 2011 Oct; 17(10):1436-42. PubMed ID: 21703971
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Donor selection for adoptive immunotherapy with NK cells in AML patients: Comparison between analysis of lytic NK cell clones and phenotypical identification of alloreactive NK cell repertoire.
    Meazza R; Ruggeri L; Guolo F; Minetto P; Canevali P; Loiacono F; Ciardelli S; Bo A; Luchetti S; Serio A; Zannoni L; Retière C; Colomar-Carando N; Parisi S; Curti A; Lemoli RM; Pende D
    Front Immunol; 2023; 14():1111419. PubMed ID: 36865545
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
    Hattori N; Nakamaki T
    Int J Mol Sci; 2019 Apr; 20(9):. PubMed ID: 31027331
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The anti-tumour activity of allogeneic cytokine-induced killer cells in patients who relapse after allogeneic transplant for haematological malignancies.
    Linn YC; Niam M; Chu S; Choong A; Yong HX; Heng KK; Hwang W; Loh Y; Goh YT; Suck G; Chan M; Koh M
    Bone Marrow Transplant; 2012 Jul; 47(7):957-66. PubMed ID: 21986635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.